Neogen (NEOG)
(Delayed Data from NSDQ)
$16.78 USD
+0.73 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.78 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.78 USD
+0.73 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.78 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Zacks News
4 Medical Product Stocks to Buy Amid Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. PHG, NEOG, HAE and PBH are well-poised to gain from the favorable factors.
Quipt Home Medical Corp. (QIPT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -250% and 1.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) to Advance Feline DNA Testing With New Pact
by Zacks Equity Research
Neogen's (NEOG) strategic alliance will expand feline DNA testing and strengthen its relationship with the kitty community.
Here's Why You Should Buy Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.
Neogen (NEOG) to Offer Biosecurity Products With New Pact
by Zacks Equity Research
Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.
Neogen (NEOG) Unveils New Assay for Walnut Allergens Detection
by Zacks Equity Research
Neogen's (NEOG) Veratox VIP for Walnut allergy test displays robust performance across sample types while keeping the Veratox product line's simple testing approach.
Abbott (ABT) Up 5.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen's (NEOG) Innovation Aids, Currency Headwind Stays
by Zacks Equity Research
Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.
Neogen (NEOG) Up 3.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.
Company News for Oct 11, 2023
by Zacks Equity Research
Companies in The News Are: PEP,NEOG,PLTR,TFC
Neogen (NEOG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Neogen (NEOG) give a sense of how the business performed in the quarter ended August 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Here's Why Neogen (NEOG) is Poised for a Turnaround After Losing -14.43% in 4 Weeks
by Zacks Equity Research
Neogen (NEOG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neogen (NEOG) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -21.43% and 1.23%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG), led by progress in the Food Safety business and recent product launches.
Neogen (NEOG) Gains From Strong Segmental Sales, Innovation
by Zacks Equity Research
Within the biosecurity portfolio, Neogen (NEOG) continues to record solid growth in cleaners, disinfectants and rodenticides.
High Tide Inc. (HITI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of 25% and 4.52%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -12.39% in 4 Weeks, Here's Why Neogen (NEOG) Looks Ripe for a Turnaround
by Zacks Equity Research
Neogen (NEOG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool
by Zacks Equity Research
Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on recent product launches.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Neogen (NEOG) Introduces New Genomic Data Management Tool
by Zacks Equity Research
Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.
Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.